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Abstract
Objective—Increasing evidence supports the efficacy of trauma-focused exposure therapy in the 
treatment of posttraumatic stress disorder (PTSD) and co-occurring substance use disorders. Little 
is known, however, about the mechanisms of change in treatment for patients with PTSD and co-
occurring substance use disorders. The aim of the present study was to examine whether within- 
and between-session habituation of distress and substance craving during imaginal exposure 
relates to treatment outcomes among US military Veterans with PTSD and a co-occurring 
substance use disorder (N = 54).
Method—Veterans received Concurrent Treatment of PTSD and Substance Use Disorders Using 
Prolonged Exposure (COPE), a manualized integrated treatment combining PE with cognitive 
behavioral therapy for substance use disorders as part of a larger randomized clinical trial. Self-
reported distress and craving ratings were collected during each imaginal exposure session.
Results—Data were analyzed using a series of random intercept and slope multilevel linear and 
generalized linear models. Results revealed that between-session habituation of distress and 
craving was associated with greater improvement in PTSD symptoms during treatment. Between-
session habituation of craving was also associated with a marginally greater reduction in frequency 
of substance use among participants still reporting use during treatment. Within-session 
habituation of distress was unrelated to treatment outcome.
Conclusions—Together, these findings indicate that habituation in both distress and craving 
may be important in maximizing treatment outcome for patients with PTSD and comorbid 
substance use disorders.
*Corresponding Author: Christal L. Badour, PhD, Department of Psychology, 106b Kastle Hall, University of Kentucky, Lexington, 
KY 40506, Phone: 859-323-3817, christal.badour@uky.edu. 
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Individuals with co-occurring PTSD and substance use disorders suffer a more complicated 
clinical course and less successful treatment outcome compared to those with either 
diagnosis alone (Flanagan, Korte, Killeen, & Back, 2016). Although Prolonged Exposure 
(PE; Foa, Hembree, & Rothbaum, 2007) is a well-established and effective treatment 
approach for PTSD (Institute of Medicine, 2008), the “sequential model”, wherein substance 
use is treated first and PTSD treatment is deferred to another venue and/or clinician, has 
been the standard of care for treating co-occurring PTSD and substance use disorders. 
(McCauley, Killeen, Gros, Brady, & Back, 2012). It was long assumed that distress 
associated with confronting traumatic memories during PE would lead to increased 
substance use, or relapse among those in recovery (Solomon, Gerrity, & Muff, 1992). 
However, a growing number of studies suggest that trauma-related exposure therapy yields 
greater improvement in PTSD symptoms compared to traditional substance use treatments; 
and there is no evidence of associated increases in substance use, risk of relapse, or 
treatment dropout (Roberts et al., 2015; Torchalla et al., 2012).
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure 
(COPE; Back et al., 2014) is one such treatment that has received empirical support in both 
civilian and Veteran populations (Back et al., 2012, 2016; Brady, Dansky, Back, Foa, & 
Carroll, 2001, 2001; Mills et al., 2012). COPE is a 12-session cognitive-behavioral therapy 
(CBT), that integrates CBT for substance use disorders (e.g., Carroll, 1998) and PE therapy 
for PTSD (Foa et al., 2007). COPE is designed to reduce both PTSD and substance use 
disorder severity as well as to improve well-being and functioning.
Questions exist regarding the mechanisms of action underlying therapeutic change in 
integrated treatments such as COPE. Informed by the hypothesized mechanisms of exposure 
therapy outlined by emotional processing theory (EPT; Foa & Kozak, 1986), a robust 
empirical literature has examined predictors of change in PTSD symptoms during PE. EPT 
suggests that recovery from PTSD is achieved through a two-part process: 1) exposure to 
situations or memories that activate conditioned fear structures maintaining symptoms of 
PTSD, and 2) introduction of fear-incompatible information needed to develop a competing 
structure without pathological associations (Foa & McNally, 1996). Habituation of fear or 
distress during therapy occurring both within-session (W-S) and between-session (B-S) has 
been widely studied as one primary indicator of this change process. As reviewed by Foa & 
McLean (2016), B-S habituation (i.e., reduction in distress ratings from the first to the last 
imaginal exposure) predicts PTSD symptom improvement among patients receiving PE in 
most, but not all studies. In contrast, studies have generally failed to link degree of W-S 
habituation (i.e., reduction from peak distress ratings within individual imaginal exposure 
sessions) to PTSD symptom response.
Integrated treatments such as COPE may have unique mechanisms of action as compared to 
treatments designed to address either PTSD or the substance use disorder alone. Thus, the 
present study sought to expand upon previous mechanistic investigations of PE by 
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examining how W-S and B-S habituation of subjective distress and substance craving during 
COPE relates to symptom improvement among Veterans with co-occurring PTSD and 
substance use disorders. It is hypothesized that greater B-S habituation will be associated 
with more improvement in PTSD symptoms. In addition, exploratory hypotheses examined 
the association between habituation of distress and craving during PE and change in 
substance use outcomes as well as between habituation of craving and change in PTSD 
symptoms.
Method
Participants
Participants were 54 Veterans of the United States military (92.6% male; Mage = 39.72, SD 
= 10.98) with current PTSD and substance use disorders allocated to the COPE arm of a 
larger, randomized clinical trial (Back et al., 2016). Veterans were recruited via flyers posted 
in the local Veterans Affairs (VA) and community hospitals, newspaper advertisements, and 
advertisements placed online (e.g., Craigslist). Inclusion criteria were: 1) U.S. military 
veteran status, 2) 18-65 years old, 3) met DSM-IV diagnostic criteria for current PTSD and 
had a score of > 50 on the Clinician-Administered PTSD Scale; and 4) met DSM-IV 
diagnostic criteria for a current substance use disorder and had used substances in the past 
90 days. Exclusion criteria were: 1) ongoing enrollment in another treatment for PTSD or 
substance use, 2) suicidal or homicidal ideation with intent, 3) psychiatric conditions that 
would likely require a higher level of care or could interfere with treatment (e.g., psychotic 
disorder, dissociative identity disorder), and 4) severe cognitive impairment. Psychotropic 
medication use (63.0%) had to be stable for four weeks prior to enrollment. Table 1 presents 
sample demographic and diagnostic information.
Procedure
Following informed consent, participants completed an interview and self-report 
assessments. Treatment consisted of 12 weekly, individual, 90-min sessions (Back et al., 
2014) focused on goal-setting, psychoeducation, and methods for coping with cravings 
(sessions 1-3); in-vivo exposure (sessions 3-12); and imaginal exposure (sessions 4-11). 
Flexible application of the protocol allowed for up to two sessions to deviate from the 
intended procedure to address acute clinical issues. Participants were classified as treatment 
completers if they attended at least 8 of the 12 sessions and at least 3 imaginal exposure 
sessions (Brady et al., 2001).
Measures
PTSD symptoms—The CAPS (Blake et al., 1995), a semi-structured clinical interview 
considered the gold standard for PTSD assessment, was used to obtain a current diagnosis of 
PTSD and ensure a symptom severity score ≥ 50 at baseline. The PTSD Checklist-Military 
(PCL-M; Weathers, Litz, Huska, & Keane, 1994), a well-established 17-item self-report 
measure of PTSD symptoms based on DSM-IV criteria, was administered weekly to assess 
change in PTSD symptoms during treatment. Internal consistency of the PCL-M was good 
to excellent in the current sample (α = .86 - .96). Minimal missingness (< 1%) of individual 
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items for available observations on the PCL-M was imputed using last observation carried 
forward (LOCF).
Substance use—The Mini International Neuropsychiatric Interview (MINI; Sheehan et 
al., 1998), a structured interview with strong psychometric properties, was used to obtain a 
current diagnosis of a substance use disorder at baseline. Percent days use of any substances 
(PDU) was assessed for two months prior to baseline and weekly during treatment using the 
Timeline Follow-Back (TLFB; Sobell & Sobell, 1992). The TLFB uses a calendar and other 
memory prompts to stimulate recall of substance use. The TLFB yields consistently high 
test-retest correlations and correlates well with other self- and collateral-reports (Carey, 
1997).
Subjective distress—Levels of subjective distress were monitored at the beginning and 
end of each imaginal exposure, as well as every 5 minutes during the imaginal exposure 
using the Subjective Units of Distress Scale (SUDS; Wolpe & Lazarus, 1966), a verbal 
rating of subjective distress from 0 (no distress) to 100 (the worst distress ever experienced). 
Consistent with previous work (Nacasch et al., 2015), W-S habituation for each imaginal 
exposure was computed by subtracting the peak SUDS rating from the post SUDS rating, 
yielding measures of average W-S habituation (across all imaginal exposures), early W-S 
habituation (during the first imaginal exposure), and late W-S habituation (during the final 
imaginal exposure). B-S habituation in SUDS was calculated by subtracting the peak SUDS 
from the first imaginal exposure from the peak SUDS of the final imaginal exposure session.
Substance craving—Subjective ratings of substance craving were collected at the 
beginning and end of each imaginal exposure session using a verbal rating scale ranging 
from 0 (no craving) to 100 (highest craving possible). B-S habituation in substance craving 
was calculated by subtracting the post-craving rating for the first imaginal exposure session 
from the post-craving rating for the final imaginal exposure session.
Data Analytic Approach
Slopes of change in PTSD symptoms and substance use from baseline through session 12 
were examined using a series of unconditional and conditional random intercept and slope 
multilevel linear and generalized linear models with unstructured covariance matrices using 
robust maximum likelihood (MLR) estimation in Mplus version 7.4 (1998-2012). Session 
was coded as zero (intercept) at baseline for all participants. Due to the nature of substance 
use data (i.e., zero-inflation), substance use was analyzed using two-part modeling (Olsen & 
Schafer, 2001), in which separate parts are analyzed in the same model. One part of the 
model captures the likelihood of using (yes/no) and the other part captures frequency of use 
(i.e., percent days using any substances), conditional on using. W-S and B-S SUDS and 
craving habituation were mean-centered prior to entry into conditional models as level 2 
predictors. Model fit was examined via -2 log likelihood comparisons. Significant 
interactions between habituation indices and PTSD/substance use change slopes were 
probed based on +/- 1 standard deviation from the mean on the habituation predictors (Shek 
& Ma, 2011).
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Results
On average, participants attended 8.83 sessions (SD = 4.12; Range: 0 – 12). Fifty four 
percent of participants completed all 12 sessions (n = 29), and 66.7% (n = 36) completed 8 
out of 12 sessions (with at least 3 imaginal exposures) and were considered treatment 
completers. Completers and non-completers (n = 18) did not differ significantly at baseline 
on any of the sociodemographic or clinical characteristics. Table 2 displays means and 
standard deviations for W-S and B-S habituation in SUDS and craving ratings.
PTSD Symptoms: PCL-M
Table 3 displays results from the unconditional growth model as well as the conditional 
models with W-S and B-S habituation indices and their interactions with linear and quadratic 
session as predictors of PCL-M scores across treatment. There were significant linear and 
quadratic effects of session on PCL-M scores in the unconditional model, indicating that 
PTSD symptoms improved significantly across treatment, and the rate of change was not 
constant. Figure 1A displays the unconditional growth model for PCL-M scores across 
treatment, as well as raw means and corresponding standard errors at each session. In the 
conditional models W-S SUDS habituation (early, late, average) was unrelated to either 
initial PCL-M scores or rates of change. In contrast, B-S SUDS and craving habituation 
were both associated with more improvement in PCL-M scores. As displayed in Figure 2A 
participants scoring 1 SD above the mean, as compared to 1 SD below, in terms of B-S 
SUDS habituation scored an average of 13.58 points lower on the PCL-M at the end of 
treatment. Figure 2B demonstrates that participants scoring 1 SD above the mean, as 
compared to 1 SD below, on B-S craving habituation scored an average of 8.44 points lower 
on the PCL-M at the end of treatment.
Substance Use: TLFB
Unconditional model fit for predicting substance use was best when including the linear but 
not quadratic effect of session and restricting the covariance between the intercepts of use 
(any use vs. non-use) and frequency of use (PDU, conditional on use) to zero. Tables 4 (any 
use) and 5 (PDU) display results from the unconditional models as well as the conditional 
models with W-S and B-S habituation indices and their interactions with linear session as 
predictors of substance use across treatment. Figure 1B displays the probability of any use 
across sessions and Figure 1.C displays PDU across sessions, conditional on usage. There 
was a significant linear effect of session on probability of using and on PDU, indicating that 
both the likelihood of use and frequency of use declined significantly across treatment. W-S 
(early, late, average) and B-S SUDS habituation were unrelated to change in probability of 
using and PDU. However, higher late W-S SUDS habituation was linked to an increased 
probability of reporting use at baseline, while lower B-S SUDS habituation was linked to 
both an increased probability of using and a higher PDU at baseline. B-S craving habituation 
was marginally associated with a greater decrease in PDU across treatment for those who 
were using (p = .07). As displayed in Figure 2C, participants who were 1 SD above the 
mean, as compared to 1 SD below the mean, in terms of B-S craving habituation reported 
21.54% fewer days of use at the end of treatment.
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Discussion
This study tested whether W-S and B-S SUDS and B-S craving habituation predicted change 
in PTSD symptoms and substance use during COPE. The hypothesis that B-S SUDS 
habituation would predict improvement in PTSD symptoms was supported. This finding 
replicates prior work demonstrating that B-S, and not W-S, SUDS habituation predicts 
PTSD symptom improvement (Foa & McLean, 2016). Although B-S SUDS habituation was 
unrelated to change in substance use, participants reporting less B-S SUDS habituation were 
more likely to have been using (or using more frequently) at the start of treatment. It will be 
important for future studies to examine how baseline substance use patterns affect PTSD 
treatment response as well as purported mechanisms of change during integrated treatments.
Results further demonstrated that B-S craving habituation was linked to greater 
improvement in PTSD symptoms and marginally greater improvement in frequency of 
substance use. Although there is some evidence that repeated exposure to alcohol-related 
cues may lead to decreased use and risk of relapse among individuals with alcohol use 
disorders (e.g., Drummond, & Glautier, 1994), this is the first study to document an 
association between exposure-related changes in craving in response to trauma cues, and 
improvement in PTSD and substance use. Although further research and replication are 
needed, the influence of B-S craving habituation may be important in advancing our 
understanding of integrated treatments.
Several limitations of the study warrant consideration. The relatively small sample consisted 
of primarily male military Veterans, which may limit the generalizability of the results. The 
limited measure of craving precluded examination of how W-S craving habituation may 
relate to treatment outcome. Future studies should consider incorporating more frequent 
assessments of craving, perhaps in parallel with SUDS ratings. Finally, this study focused on 
habituation as a hypothesized mechanism of change. Alternative mechanisms including 
reductions in trauma-related negative cognitions (e.g., “The world is dangerous”; Foa & 
McLean, 2016) and expectancy violation (e.g., “If I confront my traumatic memory, I will 
lose control”; Craske, Treanor, Conway, Zbozinek, & Vervliet, 2014) are being increasingly 
recognized as critical mediators of PTSD symptom change during exposure therapy. Future 
studies should examine habituation along with these factors in order to build a more 
complete picture of relevant change mechanisms.
Despite these limitations, this study adds substantially to the literature as the first to examine 
how SUDS and craving habituation relate to treatment outcome in a sample receiving an 
integrated, exposure-based treatment for PTSD and co-occurring substance use disorders. 
These findings converge with those of previous studies suggesting that B-S SUDS 
habituation, rather than W-S SUDS habituation, should be a focus of treatment during 
exposure. This work further indicates that greater attention needs to be paid to changes in 
craving across treatment, as this may be an important and under recognized mechanism of 
change in patients receiving treatment for comorbid PTSD and substance use disorders.
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Figure 1. Means, standard errors, and unconditional growth models for change in (A) PTSD 
symptoms, (B) percent of participants using any substance, and (C) percent days using any 
substances, conditional on use
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Figure 2. (A) Estimated change in PTSD symptoms across treatment as a function of between-
session SUDS habituation, (B) Estimated change in PTSD symptoms across treatment as a 
function of between-session SUDS craving habituation, (C) Estimated change in percent days 
using any substances, conditional on use, as a function of between-session craving habituation
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Table 1
Sample Demographic and Diagnostic Information
n %
Race
 White 37 68.5
 African American/Black 16 29.6
 Other 1 1.9
Hispanic Ethnicity 2 3.7
Substance Use Disorder Diagnoses
 Alcohol Use Disorder Only 33 61.1
 Alcohol and Drug Use Disorders 15 27.8
 Drug Use Disorder Only 6 11.1
Drug Use Disorders
 Cocaine 8 14.8
 Opioid 9 16.7
 Marijuana 5 9.3
 Sedative/Hypnotic/Anxiolytic 1 1.9
 Other 1 1.9
Current Major Depressive Episode 21 38.9
Current Anxiety Disorder other than PTSD 29 53.7
PTSD = posttraumatic stress disorder.
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Table 2
Mean (SDs) for the Within- and Between-Session SUDS Habituation and Between-Session 
Craving Habituation
n Mean SD
Average within-session SUDS habituation 46 -16.74 12.37
 Average Peak SUDS 46 60.59 20.41
 Average Post SUDS 46 43.81 23.41
Early within-session SUDS habituation 46 -22.13 22.83
 Early Peak SUDS (first imaginal exposure) 46 80.44 18.37
 Early Post SUDS (first imaginal exposure) 46 58.30 27.07
Late within-session SUDS habituation 36 -8.86 13.08
 Late Peak SUDS (last imaginal exposure) 36 38.33 23.72
 Late Post SUDS (last imaginal exposure) 36 29.47 21.54
Between-session SUDS habituation 36 -40.56 26.51
Between-session craving habituation 34 -15.03 28.98
Note: SUDS = subjective units of distress. Eight participants withdrew from the study prior to session 4. Due to pressing clinical issues, the first 
imaginal exposure occurred during session 5 for 2 participants and during session 6 for 1 participant. Late within-session SUDS habituation and 
between-session SUDS habituation ratings were available for all treatment completers (n = 36). The final imaginal exposure session occurred prior 
to session 11 for 8 treatment completers. In these cases, ratings from the last completed imaginal exposure were used to calculate late within-
session and between-session SUDS as well as between-session craving habituation. Craving ratings were not assessed for 2 participants.
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